Search Results
Sep 08, 2026, 08:20 ET Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo
solutions. Meanwhile, Fosun Pharma has consolidated its core technical platforms including but not limited to antibodies and antibody-drug conjugates (ADC), small molecules and cell therapy. Additionally, we also actively advance cutting-edge therapeutic modalities such as radiopharmaceuticals and small
More news about: Accro Bioscience (Suzhou) Limited
Sep 08, 2026, 08:00 ET Kelun-Biotech's Partner Windward Bio Announces Positive Phase 2 Results of SKB378/WIN378 in Asthma, and Initiates Phase 3 Study
in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please
More news about: Kelun-Biotech
Sep 04, 2026, 07:00 ET Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate
Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for ACE723, a GPC3-targeted dual-payload antibody-drug conjugate (ADC) developed using Acepodia's proprietary Antibody-Dual-Drugs Conjugation (AD2C) platform for the treatment of unresectable or metastatic hepatocellular
More news about: Acepodia, Inc.
Sep 03, 2026, 10:31 ET Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth | DelveInsight
a broader population. GSK's Risvutatug rezetecanADC targeting B7-H3Risvutatug rezetecan (Ris-Rez; GSK5764227; HS-20093) is an investigational antibody-drug conjugate (ADC) designed to selectively target B7-H3, a cell-surface protein highly expressed
More news about: DelveInsight Business Research, LLP
Sep 03, 2026, 08:30 ET Reduce ADC Conjugation Risk with Consistent Antibody Quality, Upcoming Webinar Hosted by Xtalks
predictable ADC performance.TORONTO, Sept. 3, 2026 /PRNewswire/ -- Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies with potent cytotoxic payloads for targeted oncology. While an ADC consists
More news about: Xtalks
Sep 03, 2026, 07:15 ET ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference
days.About ADC TherapeuticsADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA® (loncastuximab tesirine-lpyl).ADC Therapeutics'
More news about: ADC Therapeutics SA
Sep 02, 2026, 23:26 ET 亞洲生技大會台康生物藥開發平臺吸睛，劉理成談 CDMO 該往何方
2026年9月3日 /美通社/ -- 今年亞洲生技大會（BIO Asia–Taiwan 2026），台康生技（6589, EirGenix）在其參展攤位與 Mini Talks 系列活動中展示生物藥開發端到端解決方案，涵括質體 DNA（pDNA）製造、生物分析技術、表現系統選擇，到 ADC 製程策略等關鍵面向，分享如何透過平臺、技術與深厚經驗，協助客戶降低風險並提升開發效率。台康生技創辦人暨董事長劉理成接受基因線上專訪時表示，在生物藥快速演進的時代，真正決定一項產品能否順利推進臨床、甚至成功商業化的，市場關注的新藥機制固然重要，但背後的平臺技術、分析能力與 CMC（化學、製造與管制）策略也不可忽視。他直言，即便抗體藥物複合體（ADC）、雙特異性抗體（Bispecific
More news about: 基因線上
Sep 02, 2026, 17:00 ET Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.Backed
More news about: Akeso, Inc.
Sep 02, 2026, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for September 2026
AAV Potency Assurance with NGS Sequence AnalysisSep 24 - Optimizing Line Setup to Reduce Interventions and BreakageSep 24 - Reduce ADC Conjugation Risk with Consistent Antibody QualitySep 28 - Future-Proofing Your CMC Strategy: Managing Critical Starting Material ChangesSep
More news about: Xtalks
Sep 02, 2026, 08:00 ET Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences:Cantor Global Healthcare Conference
More news about: Whitehawk Therapeutics, Inc.
Sep 01, 2026, 03:53 ET SIBIONICS présente le GS3 à Melbourne, pour une surveillance de la glycémie plus efficace et activée par l'intelligence artificielle
en matière de capteurs et son système de surveillance de la glycémie basé sur l'intelligence artificielle à l'occasion du congrès conjoint IDF-WPR, ADC et Metabolic Diseases 2026, qui s'est déroulé à Melbourne du 18 au 21 août. Sur le stand n° 1 et grâce à un colloque scientifique et à des entretiens
More news about: SIBIONICS
Aug 31, 2026, 08:22 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
Company's proprietary ADC platform incorporates optimized linker technologies designed to enable tumor-selective payload release and supports multiple Pipeline 2.0 ADC candidates, including CS5007 (EGFR and HER3 bispecific ADC), CS5006 (ITGB4 ADC), CS5008 (DLL3 and SSTR2 bispecific ADC), etc. The Company
More news about: CStone Pharmaceuticals
Aug 31, 2026, 08:00 ET T-MAXIMUM B7-H3-Targeted Allogeneic CAR-T Therapy MT027 Receives FDA Fast Track Designation, Accelerating Global Development for Intracranial Solid Tumors
conjugates (ADCs), antibody therapeutics and cell therapies all being actively pursued. In July 2026, Hansoh Pharmaceutical announced that its B7-H3 ADC, HS-20093, met the primary endpoint of progression-free survival (PFS) as assessed by an independent review committee (IRC) in patients with relapsed
More news about: T-MAXIMUM PHARMACEUTICAL
Aug 31, 2026, 07:57 ET SIBIONICS presenta GS3 en Melbourne, impulsando un monitoreo de glucosa en sangre más eficiente basado en IA
presentó su innovadora tecnología de sensores y monitoreo de la glucosa en sangre mediante inteligencia artificial en el congreso conjunto IDF-WPR, ADC y Metabolic Diseases 2026, celebrado en Melbourne del 18 al 21 de agosto. A través del stand n.º 1, un simposio científico y entrevistas in situ con
More news about: SIBIONICS
Aug 31, 2026, 07:05 ET SIBIONICS präsentiert den GS3 in Melbourne und treibt damit eine effizientere, KI-gestützte Glukoseüberwachung voran
2026 /PRNewswire/ -- SIBIONICS präsentierte seine Sensorinnovation und die KI-gestützte Glukoseüberwachung auf dem gemeinsamen Kongress von IDF-WPR, ADC und Metabolic Diseases 2026, der vom 18. bis 21. August in Melbourne stattfand. Durch den Stand Nr. 1, ein wissenschaftliches Symposium und Interviews
More news about: SIBIONICS
Aug 31, 2026, 06:00 ET IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
this potential first-in-class combination has the potential to enhance durability of IDEAYA's TOP1-payload based ADC pipeline, including IDE849 and IDE034 (Phase 1 B7H3/PTK7 Bispecific TOP1 ADC).DLL3 has been reported to be upregulated in multiple solid tumor types, including in SCLC, NEC and melanoma,
More news about: IDEAYA Biosciences, Inc.
Aug 31, 2026, 00:19 ET SIBIONICS Showcases GS3 in Melbourne, Advancing More Efficient, AI-Powered Glucose Monitoring
Aug. 31, 2026 /PRNewswire/ -- SIBIONICS showcased its sensor innovation and AI-powered glucose monitoring at the joint IDF-WPR, ADC and Metabolic Diseases 2026 congress, held in Melbourne from 18–21 August. Through Booth #1, a scientific symposium and on-site interviews with Credentialled
More news about: SIBIONICS
Aug 28, 2026, 12:30 ET 復星國際舉行2026年中期業績發佈會：打通「任督二脈」，在優勢產業加速發展
業務軌道，保持高強度科創投入，僅今年上半年科創投入便達到人民幣42億元，同比上升16.7%。復星國際聯席CEO陳啟宇介紹，復星在醫療健康領域，主要圍繞中國、美國、全球新興市場三個維度的需求進行佈局，經過十多年努力，搭建了單抗、雙抗、多抗、ADC、融合蛋白、小分子、自體CAR-T、新型通用型CAR-T、核藥等技術平台，構建了涵蓋實體瘤、血液腫瘤、免疫炎症、神經退行性疾病、心血管、代謝等疾病領域的高價值研發管線。同時，也在持續打造開放式創新生態，與更多全球性公司進行全方位的合作。陳啟宇認為，中國生物醫藥企業在創新研發上深耕近20年後，當下都面臨着一個必須要突破的全球化核
More news about: 復星
Aug 28, 2026, 08:03 ET Formosa Pharmaceuticals Files Clinical Trial Application for TSY-110, an Antibody-Drug Conjugate Biosimilar Targeting HER2-Positive Breast Cancers
momentous step toward fulfilling our goal of delivering world-class, accessible ADC options to oncologists and patients."About TSY-110TSY-110, also designated as EG12043, is an antibody-drug conjugate (ADC) biosimilar co-developed by Formosa Pharmaceuticals and EirGenix, Inc. (TWSE:
More news about: Formosa Pharmaceuticals Inc.,
Aug 28, 2026, 07:31 ET Asieris Pharmaceuticals Releases 2026 Semi-Annual Report: Core Product Commercialization Delivers, Entering a Harvest Period as the Company Accelerates Its Transition to Biopharma
high-potential pipeline programs by leveraging its targeted and AI-driven drug discovery platform, drug-device combination platform, and innovative ADC technologies. During the reporting period, multiple pipeline programs achieved positive progress, demonstrating innovative advantages and competitive
More news about: Asieris
Aug 28, 2026, 00:08 ET DualityBio Enters a Global Collaboration and License Agreement with Genentech to Develop Next-Generation ADCs Built on DualityBio's DUPAC Novel-Payload Platform
care."About DUPACDUPAC (DualityBio Unique Payload Antibody Conjugate) is DualityBio's proprietary platform for ADC payloads with novel mechanisms of action, and one of four ADC technology platforms developed by the Company alongside DITAC, DIMAC and DIBAC. DUPAC encompasses several payloads, including
More news about: Duality Biotherapeutics, Inc.
Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
partners, including Pfizer, GSK, Biokin, and MediLink. These collaborations cover agents such as EGFR/HER3 bispecific ADC, TROP2/HER3 bispecific ADC, B7H3 ADC, FGFR2b ADC, TROP2 ADC, and Nectin-4 ADC across high-incidence malignancies.Looking further ahead, the Company's frontier programs continue to push
More news about: Akeso, Inc.
Aug 27, 2026, 10:15 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
Company's proprietary ADC platform incorporates optimized linker technologies designed to enable tumor-selective payload release and supports multiple Pipeline 2.0 ADC candidates, including CS5007 (EGFR and HER3 bispecific ADC), CS5006 (ITGB4 ADC), CS5008 (DLL3 and SSTR2 bispecific ADC), etc. The Company
More news about: CStone Pharmaceuticals
Aug 27, 2026, 07:02 ET Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion
postoperative "chemo-sparing" regimen. HLX43, a core asset in the innovative pipeline, is a potential best-in-class (BIC) broad-spectrum anti-tumor PD-L1 ADC. It has demonstrated preliminary clinical efficacy characterized by high efficacy and low toxicity across multiple solid tumors, including non-small
More news about: Fosun
Aug 26, 2026, 12:03 ET Vesselon Issued Patent and New Data Changes the Therapeutic Index of Antibody-Based Drugs
targeted tumor while reducing off-target uptake that can cause toxicity. A large percentage of patients on checkpoint inhibitor, antibody drug conjugate (ADC) and bispecific drugs have to reduce dose, discontinue treatment or obtain little clinical benefit from treatments that cost hundreds of thousands of
More news about: Vesselon Inc.